Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis and Johns Hopkins join forces in asthma

This article was originally published in Scrip

Executive Summary

Sanofi-Aventisand the Johns Hopkins University School of Medicine are to jointly discover and develop new methods to treat respiratory diseases, in particular severe asthma and chronic obstructive pulmonary disease, as well as immuno-allergic diseases. Under a three-year agreement, the university's division of allergy and clinical immunology and the French company will work on new target identification, assay development and compound screening, and will collaborate on the design of potential clinical studies and the selection of biomarkers. Sanofi-Aventis already markets the allergy treatment Allegra (fexofenadine HCl) and has a number of NCEs at very early stages of development for asthma.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts